Payment overview · 2025
General Payments
$10,442.80
232 reported records · 19 companies
Healthcare provider profile · identity verified
Abdul G Bahro, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · FLOWOOD, MS · NPI 1447286612
Verified facts
What the public records show
CMS Open Payments records show Abdul G Bahro, MD received $10,442.80 in general payments during 2025 across 232 reported records.
Bard Peripheral Vascular, Inc. accounted for 61.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $6,443.31 | 61.7% | 59 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $726.31 | 7.0% | 38 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $669.28 | 6.4% | 30 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $504.34 | 4.8% | 6 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $466.10 | 4.5% | 23 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $313.14 | 3.0% | 31 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $303.99 | 2.9% | 15 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $233.68 | 2.2% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $224.01 | 2.1% | 9 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $126.07 | 1.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $105.39 | 1.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$99.23 | 0.9% | 4 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $54.39 | 0.5% | 5 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $49.83 | 0.5% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $29.31 | 0.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.86 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.69 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.31 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.56 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,000.00 | 1 |
| Food and Beverage | $4,779.00 | 229 |
| Travel and Lodging | $663.80 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $1,358.68 | 46 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $466.10 | 23 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $410.62 | 5 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $313.14 | 31 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $308.99 | 15 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $233.68 | 3 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $211.43 | 7 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $157.98 | 4 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $130.13 | 2 | 2025 |
Source payment records
|
|||||
| EXCLUDER Conformable AAA Endoprosthesis with Active Control Normalized: excluder conformable aaa endoprosthesis with active control |
Device | W. L. Gore & Associates, Inc. | $126.07 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $105.39 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $99.23 | 4 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $93.72 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $68.63 | 7 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $66.31 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $54.39 | 5 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $48.44 | 5 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $43.30 | 2 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $37.72 | 6 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $30.79 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $29.31 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $28.03 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| PERCIVA ICD VR Normalized: perciva icd vr |
Device | Boston Scientific Corporation | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| myLUX Patient Kit with mobile device Normalized: mylux patient kit with mobile device |
Device | Boston Scientific Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $12.58 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $9.84 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $5.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 310 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 77 |
| Eliquis | Apixaban | 202 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 67 |
| Carvedilol | Carvedilol | 136 | 52 |
| Amiodarone Hcl | Amiodarone Hcl | 132 | 44 |
| Entresto | Sacubitril/Valsartan | 119 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 35 |
| Furosemide | Furosemide | 83 | 34 |
| Xarelto | Rivaroxaban | 54 | 14 |
| Lisinopril | Lisinopril | 47 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 18 |
| Atenolol | Atenolol | 46 | 14 |
| Brilinta | Ticagrelor | 46 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 18 |
| Labetalol Hcl | Labetalol Hcl | 33 | 13 |
| Losartan Potassium | Losartan Potassium | 32 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | 13 |
| Omeprazole | Omeprazole | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,442.80 · 232 records | Bard Peripheral Vascular, Inc. | ARTIX MT, ASSURITY, AURYON LASER SYSTEM 100-120 VAC, AVEIR, AVVIGO Guidance System, Ambulatory Monitoring & Diagnostics Undivided, Barostim Neo System, CARDIOMEMS, CARDIVA VASCADE 6/7F VCS, CLOT MANAGEMENT, Crosser IQ, ELIQUIS, ELUVIA, EMBLEM MRI S-ICD, ESPRIT, EXCLUDER Conformable AAA Endoprosthesis with Active Control, FLOWTRIEVER, GALLANT, General - Brady, General - Stents, INSPIRE, Indigo System, Kerendia, LM Undivided, LUTONIX Drug Coated Balloon, LUX-Dx Insertable Cardiac Monitor, LifeStream, LifeVest, NURTEC ODT, PERCIVA ICD VR, PERCLOSE PROSTYLE, Penumbra System, Ranger, RotarexS 6 F x 135 cm, SYMPLICITY G3, Serrantor, VERQUVO, WATCHMAN Access System, myLUX Patient Kit with mobile device | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error